

Arturo Loaiza-Bonilla, M.D., M.S.Ed.

Dr. Arturo Loaiza-Bonilla, M.D., M.S.Ed., is the Co-Founder and Chief Medical Officer at Massive Bio, a global industry leader in connecting patients to clinical trials using artificial intelligence. An internationally renowned medical oncologist and researcher, Dr. Bonilla has a distinguished academic and clinical career in AI applications in healthcare, precision medicine oncology, immunotherapy, clinical trial design, digital health, entrepreneurship, and patient advocacy. Dr. Loaiza-Bonilla is board certified in both medical oncology and hematology and has extensive experience in the diagnosis and treatment of genomic biomarker-driven cancers and serves as the Systemwide Chief of Hematology and Oncology at St. Luke's University Health Network, leading a dynamic oncology team spanning 15 hospitals across 11 counties in Pennsylvania and New Jersey, all part of a nationally recognized healthcare system.

Before joining St. Luke's, Dr. Loaiza-Bonilla was enterprise Chair of Research at Capital Health, and served as vice chairman of the Department of Medical Oncology at Cancer Treatment Centers of America in Philadelphia, Pennsylvania, as well as enterprise director of research, where he provided leadership and expertise to their oncology trial portfolio across 5 cancer centers and over 70 NCTN and industry-sponsored clinical trials. His research has been extensively published in the most prominent journals and meetings in oncology, and he has been recipient of NIH funding to advance digital health and artificial intelligence tools for cancer research. He was also Faculty at the University of Pennsylvania School of Medicine; Drexel University College of Medicine, and currently as Associate Professor at Lewis Katz School of Medicine at Temple University in Philadelphia.

Throughout his stellar career, Dr. Loaiza-Bonilla has held numerous leadership positions such as President of the Pennsylvania Society of Oncology and Hematology and President of Global Alliance for Patient Access, ASCO Committee member, CancerX – Moonshot founding member, and editorial board of several oncology journals. In 2018, he was recognized as Philadelphia Business Journal's Forty Under 40, in 2019 he was bestowed the Influencers of Healthcare Award – Outstanding Healthcare Provider award by the Philadelphia Inquirer, and in 2021 he was chosen as recipient of '40 under 40 in Cancer' accolade. He has also been selected in Castle Connolly's and Philadelphia Magazine's Top Doctors listing since 2018, and writes a monthly globally syndicated column for WebMD/Medscape on 'Practical AI'.